Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

NCT03630120 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Lack of efficacy

Conditions

Thyroid Cancer
Thyroid Cancer, Medullary
Differentiated Thyroid Cancer
Papillary Thyroid Cancer
Follicular Thyroid Cancer
Poorly Differentiated Thyroid Gland Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Sorafenib
DRUG: Cabozantinib
DRUG: Vandetanib

Sponsor

H. Lee Moffitt Cancer Center and Research Institute